NCT07387679

Myo-inositol Versus Metformin in Patients With Polycystic Ovarian Syndrome to Treat Obesity

Comparison of Myo-inositol Versus Metformin for Treating Obesity in Patients With Polycystic Ovarian Syndrome

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Muhammad Aamir Latif · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

There are considerable gaps in the comparative effectiveness and tolerability of myo-inositol and metformin for treating obesity in patients with polycystic ovarian syndrome (PCOS). The current study aimed to give insights comparing myo-inositol versus metformin for treating obesity in patients with PCOS.

Detailed description

A review of the literature reveals inconsistent outcomes of myo-inositol vs metformin in the treatment of obesity and metabolic disorders in patients with PCOS, with comparable results and myo-inositol frequently demonstrating superior tolerability and reduced gastrointestinal side effects relative to metformin. When treating obesity in women with PCOS, practicing gynecologists would be able to select more appropriate medications by gathering data from local contexts. It will lessen psychological consequences associated with obesity, such as discrimination, stigma, low self-esteem, and poor quality of life.

Conditions

• Polycystic Ovarian Syndrome

Interventions

Type	Name	Description
DRUG	Myo-inositol	Women were given tablet myo-inositol 1 gm twice a day for 3 months.
DRUG	Metformin	Women received metformin 250 mg three times daily for 3 months.

Timeline

• Start date: 2024-11-29
• Primary completion: 2025-05-28
• Completion: 2025-05-28
• First posted: 2026-02-04
• Last updated: 2026-02-04

Locations

1 site across 1 country: Pakistan